F46. LUMATEPERONE (ITI-007): FAVORABLE SAFETY PROFILE IN AN OPEN LABEL SAFETY SWITCHING STUDY FROM STANDARD-OF-CARE ANTIPSYCHOTIC THERAPY IN PATIENTS WITH SCHIZOPHRENIA

Por Davis, Robert, Dmitrienko, Alex, Glass, Steven, Kozauer, Susan, Saillard, Jelena, Weingart, Michal, Satlin, Andrew, Mates, Sharon, Correll, Christoph, Vanover, Kimberly
Publicado no Schizophr Bull (2018)

S44. LUMATEPERONE (ITI-007) FOR THE TREATMENT OF SCHIZOPHRENIA: PLACEBO-CONTROLLED CLINICAL TRIALS AND AN OPEN-LABEL SAFETY SWITCHING STUDY

Por Vanover, Kimberly, Dmitrienko, Alex, Glass, Steven, Kozauer, Susan, Saillard, Jelena, Weingart, Michal, Satlin, Andrew, Mates, Sharon, Correll, Christoph, Davis, Robert
Publicado no Schizophr Bull (2018)

S117. FAVORABLE LONG-TERM SAFETY PROFILE OF LUMATEPERONE IITI-007): RESULTS FROM A 12 MONTH OPEN LABEL SAFETY STUDY FOR LUMATEPERONE IN PATIENTS WITH STABLE SYMPTOMS OF SCHIZOPHREN...

Por Vanover, Kimberly, Satlin, Andrew, Durgam, Saresh, Weingart, Michal, Saillard, Jelena, Sanchez, Juan, Hossain, Shawon, Glass, Steven, Kozauer, Susan, Mates, Sharon, Davis, Robert
Publicado no Schizophr Bull (2019)